CPRX
Catalyst Pharmaceuticals, Inc.24.19
+0.01+0.04%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
2.97BP/E (TTM)
14.15Basic EPS (TTM)
1.71Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Catalyst Pharmaceuticals posted Q3 revenue of $148.4M, up 15.3% y/y from $128.7M, driven by FIRDAPSE at $92.2M (+16.2% y/y) and AGAMREE at $32.4M (from $15.0M), while FYCOMPA fell to $23.8M (-25.8% y/y) amid generic entry. Operating income climbed to $66.3M (+30.2% y/y), gross margins held firm above 84%, and diluted EPS hit $0.42 (vs $0.35), reconciling to 127M shares with mild anti-dilution from 2.6M options. Cash swelled to $689.9M on $163.8M operating cash flow (capex negligible), no debt. AGAMREE ramps smartly. Patent suits linger.
8-K
Q3 revenues hit $148.4M
Catalyst Pharmaceuticals posted Q3 2025 net product revenues of $148.4 million, up 17.4% year-over-year, fueled by FIRDAPSE at $92.2 million and surging AGAMREE at $32.4 million despite FYCOMPA's 25.8% drop to $23.8 million post-generic entry. The company raised full-year revenue guidance to $565-585 million and launched a $200 million share repurchase through 2026, backed by $689.9 million cash. Strong balance sheet shines.
8-K
Catalyst approves $200M buyback
Catalyst Pharmaceuticals launched a $200 million share repurchase program on October 1, 2025, authorizing buybacks of its common stock through December 31, 2026, funded by existing cash reserves exceeding $650 million as of June 30, 2025, with no debt. This move signals board confidence in the biopharma's cash flow and growth strategy amid rare disease focus, yet repurchases hinge on market conditions and may be paused anytime. Strong balance sheet enables value return without derailing business development.
8-K
FIRDAPSE patent settlement with Lupin
Catalyst Pharmaceuticals settled patent litigation with Lupin over its generic FIRDAPSE, granting a U.S. market license no earlier than February 25, 2035, if FDA-approved, while terminating the New Jersey lawsuit. This follows prior settlements with Teva and Inventia, yet litigation against Hetero persists, with no assurance generics won't launch sooner. Settlement secures FIRDAPSE's branded exclusivity through 2035. Ongoing Hetero case poses entry risks.
8-K
NCCN adds LEMS guidance
Catalyst Pharmaceuticals announced on August 6, 2025, that the NCCN Guidelines for Small Cell Lung Cancer now incorporate Lambert-Eaton Myasthenic Syndrome (LEMS), amifampridine (FIRDAPSE), and VGCC antibody tests, recommending neurological evaluation and the drug as supportive care. This update highlights LEMS symptoms in 3% of SCLC patients, where 90% of cases go undiagnosed, potentially boosting awareness and treatment adoption. Early diagnosis aids outcomes. Yet risks from uncertainties could impact results.
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
HRMY
Harmony Biosciences Holdings, I
38.83-0.09
JAZZ
Jazz Pharmaceuticals plc
169.73+0.20
LBRX
LB Pharmaceuticals Inc
19.82-0.04
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
SRPT
Sarepta Therapeutics, Inc.
22.31+0.76
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75